EED - Eye Exam for Patient with Diabetes

Product Lines:
Advantage MD, EHP, Priority Partners, and USFHP.

Eligible Population:
Members 18-75 years old as of December 31 of the measurement year

Definition:
Percentage of diabetic (types 1 and 2) members who had the following:

  • Eye Exam:
    • A retinal or dilated eye exam to detect retinopathy performed by an ophthalmologist or optometrist.
    • A diagnosis of retinopathy or an eye exam with an unknown retinal status requires an annual exam.
    • If negative for retinopathy, a bi-annual exam meets criteria.
    • Members with bilateral eye enucleation are considered compliant.

Provider Specialty: Ophthalmologist or Optometrist.

New for Measure: Stratification by race and ethnicity.

Continuous Enrollment:

  • The measurement year.

Best Practice and Measure Tips

  • Provide member education on risks of Diabetic Eye Disease, and encourage scheduling annual exam.
  • Obtain eye exam reports. Notate eye care provider name and demographics in chart if report not available.
  • The dilated or retinal exam:  it is best practice to have a bilateral retinal exam unless there is history of a unilateral eye enucleation.
    • In some instances a unilateral retinal / dilated exam may be used if it meets guidelines for acceptable documentation. 
  • Documentation can be in the form of a note or letter prepared by an ophthalmologist, optometrist, PCP or other health care professional. Include: date of service, the test (indicate a dilated or retinal exam) or result, and the care provider’s credentials.
    • Documentation example: “Last diabetic retinal eye exam with John Smith, OD, was June 201X with no retinopathy.”
  • Must indicate performed by Optometrist or Ophthalmologist.
  • A slit-lamp examination must have documentation of dilation or evidence that the retina was examined to be considered compliant.
  • Examination of macula, vessels and periphery without eye dilation meets criteria for a "retinal exam."
  • A chart or photograph with date of fundus photography or retinal imaging (Example: Computerized Ophthalmic Imaging such as Optical Coherence Tomography - OCT) and one of the following is acceptable:
    • Results read by a qualified reading center or by a system that provides an artificial intelligence (AI) interpretation.
    • Results reviewed by an eye care professional.
    • Results read by a qualified reading center operating under the direction of a medical director who is a retinal specialist.
  • Prior year exam results must indicate retinopathy was not present.
  • AI Reports:
    • Acceptable: “Negative for more than mild diabetic retinopathy”: This is only considered a negative result when it is a result of an exam read by AI (IDx-DR imaging system).
    • Documentation of Provider type for AI Reports:
      • If it is noted that an Optometrist or Ophthalmologist reviewed the AI results, then choose the appropriate provider type in the dropdown.
      • Some of the reports state they were read by AI and do not list a provider. If so, choose the provider dropdown option, “Results read by a system that provides an artificial intelligence (AI) interpretation.

Not Acceptable:

  • Routine fundoscopic exam without examination of macula, vessels and periphery.
  • Documentation of "diabetes without complications."
  • Exams performed by PCP or non-eye care professionals (optician)
  • Refractive only exams
  • Exams in which only the anterior (A) chamber of the eye is examined
  • Glaucoma pressure checks
  • Unilateral post-op eye exams which do not meet guidelines for acceptable documentation

Measure Exclusions

Required Exclusions:

  • Palliative Care
  • Members in hospice or using hospice services anytime during the measurement year.
  • Members who died any time during the measurement year.
  • Frailty and Advanced Illness
  • Living in Long Term Care

NOTE: Blindness is not an exclusion for a diabetic eye exam because it is difficult to distinguish between individuals who are legally blind but require a retinal exam and those who are completely blind and therefore do not require an exam.                          

Measure Codes

  • Diabetes Mellitus Without Complications
    • ICD-10-CM: E10.9, E11.9, E13.9
  • Diabetic Eye Exam by any provider type: 
    • Current year or prior year dilated retinal screening with evidence of retinopathy: 
      • CPT II: 2022F, 2024F, 2026F
    • Current year dilated retinal screening without evidence of retinopathy: 
      • CPT II: 2023F, 2025F, 2033F
    • Prior year dilated negative retinal screening: 
      • CPT II: 3072F
    • Automated Eye Exam: 
      • CPT: 92229
  • Diabetic Retinal Screening with Eye Care Professional 
    • CPT: 67028, 67030, 67031, 67036, 67039-67043, 67101, 67105, 67107, 67108, 67110, 67113, 67121, 67141, 67145, 67208, 67210, 67218, 67220, 67221, 67227, 67228, 92002, 92004, 92012, 92014, 92018, 92019, 92134, 92201, 92202, 92227, 92228, 92230, 92235, 92240, 92250, 92260, 99203-99205, 99213-99215, 99242-99245
    • HCPCS: S0620, S0621, S3000
  • Unilateral Eye Enucleation 
    • CPT: 65091, 65093, 65101, 65103, 65105, 65110, 65112, 65114
  • Unilateral Eye Enucleation – Left 
    • ICD10PCS: Diagnosis 08T1XZZ
  • Unilateral Eye Enucleation – Right 
    • ICD10PCS: Diagnosis 08T0XZZ
  • Bilateral Modifier 
    • CPT Modifier 50

Medication List: Diabetes Medications

Description Prescription
Alpha-glucosidase inhibitors
  • Acarbose
  • Miglitol
Amylin analogs
  • Pramlintide
Antidiabetic combinations
  • Alogliptin-metformin 
  • Alogliptin-pioglitazone
  • Canagliflozin-metformin
  • Dapagliflozin-metformin
  • Dapagliflozin-saxagliptin
  • Empagliflozin-linagliptin
  • Empagliflozin-metformin
  • Empagliflozin-linagliptin-metformin
  • Ertugliflozin-metformin
  • Ertugliflozin-sitagliptin
  • Glimepiride-pioglitazone
  • Glipizide-metformin
  • Glyburide-metformin
  • Linagliptin-metformin 
  • Metformin-pioglitazone
  • Metformin-repaglinide
  • Metformin-rosiglitazone
  • Metformin-saxagliptin
  • Metformin-sitagliptin
Insulin
  • Insulin aspart 
  • Insulin aspart-insulin aspart protamine
  • Insulin degludec 
  • Insulin degludec-liraglutide
  • Insulin detemir
  • Insulin glargine
  • Insulin glargine-lixisenatide 
  • Insulin glulisine 
  • Insulin isophane human
  • Insulin isophane-insulin regular
  • Insulin lispro
  • Insulin lispro-insulin lispro protamine 
  • Insulin regular human
  • Insulin human inhaled
Meglitinides
  • Nateglinide    
  • Repaglinide
 Biguanides
  • Metformin
Glucagon-like peptide-1 (GLP1) agonists
  • Albiglutide 
  • Dulaglutide 
  • Exenatide    
  • Liraglutide
  • Lixisenatide 
  • Semaglutide
Sodium glucose cotransporter 2 (SGLT2) inhibitor
  • Canagliflozin  
  • Dapagliflozin
  • Empagliflozin
  • Ertugliflozin
Sulfonylureas
  • Chlorpropamide
  • Glimepiride  
  •  Glipizide
  • Glyburide  
  • Tolazamide 
  • Tolbutamide
Thiazolidinediones
  • Pioglitazone    
  • Rosiglitazone
Dipeptidyl peptidase-4 (DDP-4) inhibitors
  • Alogliptin   
  • Linagliptin    
  • Saxagliptin
  • Sitagliptin